TCIM
ABBV icon

TIAA CREF Investment Management’s AbbVie ABBV Stock Holding History

TIAA CREF Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$411M Sell
5,096,840
-548,757
-10% -$44.9M 0.29% 69
2018
Q4 		$520M Sell
5,645,597
-1,545,251
-21% -$136M 0.41% 51
2018
Q3 		$680M Sell
7,190,848
-965,218
-12% -$91.5M 0.44% 45
2018
Q2 		$756M Buy
8,156,066
+35,419
+0.4% +$3.46M 0.51% 35
2018
Q1 		$769M Sell
8,120,647
-2,200,493
-21% -$242M 0.52% 35
2017
Q4 		$998M Buy
10,321,140
+347,642
+3% +$32.8M 0.66% 25
2017
Q3 		$886M Buy
9,973,498
+3,093,486
+45% +$235M 0.6% 27
2017
Q2 		$499M Buy
6,880,012
+168,583
+3% +$11.3M 0.35% 62
2017
Q1 		$437M Sell
6,711,429
-359,626
-5% -$22.6M 0.31% 70
2016
Q4 		$443M Sell
7,071,055
-726,519
-9% -$44.3M 0.33% 66
2016
Q3 		$492K Sell
7,797,574
-90,589
-1% -$5.86M 0.31% 70
2016
Q2 		$488M Sell
7,888,163
-306,189
-4% -$18.7M 0.37% 54
2016
Q1 		$468M Sell
8,194,352
-1,788,916
-18% -$99.7M 0.36% 56
2015
Q4 		$591M Sell
9,983,268
-1,396,029
-12% -$80.4M 0.44% 47
2015
Q3 		$619M Sell
11,379,297
-480,430
-4% -$31.3M 0.49% 42
2015
Q2 		$797M Sell
11,859,727
-1,598,684
-12% -$104M 0.57% 34
2015
Q1 		$788M Buy
13,458,411
+599,218
+5% +$36.2M 0.55% 33
2014
Q4 		$842M Buy
12,859,193
+252,520
+2% +$15.9M 0.59% 27
2014
Q3 		$728M Buy
12,606,673
+1,507,207
+14% +$83.7M 0.52% 34
2014
Q2 		$626M Buy
11,099,466
+1,213,002
+12% +$63.6M 0.44% 42
2014
Q1 		$508M Buy
9,886,464
+1,096,650
+12% +$55.4M 0.37% 50
2013
Q4 		$464M Sell
8,789,814
-578,138
-6% -$28.4M 0.33% 58
2013
Q3 		$419M Sell
9,367,952
-77,073
-0.8% -$3.42M 0.33% 61
2013
Q2 		$390M Buy
+9,445,025
New +$413M 0.32% 59

Other funds holding ABBV

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TIAA CREF Investment Management's ABBV Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its AbbVie (ABBV) stake by 9.7% in Q1 2019, selling an estimated $44.9M and leaving 5,096,840 shares worth $411M. The position accounts for 0.29% of the portfolio, ranked #69.

TIAA CREF Investment Management first reported a position in ABBV in Q2 2013 and has held it in 24 quarters since. The position peaked at $998M in Q4 2017. 2,033 funds tracked by Wall St. Rank hold ABBV as of Q1 2019.

  • TIAA CREF Investment Management held 5,096,840 shares of AbbVie worth $411M as of Q1 2019.
  • TIAA CREF Investment Management sold 548,757 AbbVie shares in Q1 2019, an estimated $44.9M.
  • AbbVie made up 0.29% of TIAA CREF Investment Management's portfolio in Q1 2019, its #69 holding.
  • TIAA CREF Investment Management first reported a position in AbbVie in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's AbbVie position peaked at $998M in Q4 2017.
  • 2,033 funds tracked by Wall St. Rank held AbbVie as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.